Warren Street Wealth Advisors LLC Buys 129 Shares of Eli Lilly and Company (NYSE:LLY)

Warren Street Wealth Advisors LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 15.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 964 shares of the company’s stock after purchasing an additional 129 shares during the quarter. Warren Street Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $562,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in LLY. Norges Bank purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $5,992,890,000. International Assets Investment Management LLC increased its stake in Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares during the last quarter. Sapient Capital LLC bought a new stake in Eli Lilly and Company during the fourth quarter worth approximately $682,139,000. Vanguard Group Inc. raised its position in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the period. Finally, Comerica Bank bought a new stake in shares of Eli Lilly and Company in the 3rd quarter valued at approximately $345,781,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LLY. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research report on Wednesday, February 21st. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. The Goldman Sachs Group raised their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. JPMorgan Chase & Co. lifted their price target on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $787.53.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the sale, the insider now directly owns 98,554,195 shares in the company, valued at approximately $79,730,343,755. The disclosure for this sale can be found here. In the last quarter, insiders sold 762,804 shares of company stock valued at $648,109,138. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 0.7 %

LLY opened at $891.46 on Wednesday. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The stock’s fifty day moving average is $790.79 and its two-hundred day moving average is $723.56. The company has a market capitalization of $847.25 billion, a P/E ratio of 131.29, a PEG ratio of 1.92 and a beta of 0.36. Eli Lilly and Company has a 52 week low of $434.34 and a 52 week high of $894.87.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. During the same quarter last year, the firm posted $1.62 earnings per share. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. Analysts forecast that Eli Lilly and Company will post 13.76 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 10th. Stockholders of record on Thursday, May 16th were issued a $1.30 dividend. The ex-dividend date of this dividend was Wednesday, May 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.58%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.